Eliglustat
| Title | Journal |
|---|---|
| Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. | Blood cells, molecules & diseases 20141201 |
| Eliglustat: first global approval. | Drugs 20141001 |
| Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. | Journal of lipid research 20120201 |
| Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. | Journal of medicinal chemistry 20110224 |
| Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. | Blood 20101118 |
| Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. | Current opinion in investigational drugs (London, England : 2000) 20101001 |
| A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. | Blood 20100812 |
| Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. | Journal of inherited metabolic disease 20100601 |
| Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. | PloS one 20100101 |
| Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. | PloS one 20100101 |
| A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. | Molecular genetics and metabolism 20070701 |